New data at a 2026 conference showed pembrolizumab was associated with fewer pulmonary adverse events than chemotherapy for certain cancer patients. Observers are noting the importance of this event, which could shape future discussions in the field.
Medical experts say the results could inform future guidelines and practices in the healthcare field.
This is a developing situation, and further details are expected to emerge in the days ahead. The original source provides ongoing coverage.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.medscape.com/